[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100465033":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":28,"locations":34,"responsibleParty":53,"collaborators":55,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":20,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":20,"enrollmentInfo":68,"targetDuration":20,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":80,"overallStatus":36,"whyStopped":20,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Dana-Farber Cancer Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"INTRAORAL PBMT IN PATIENTS UNDERGOING alloHCT","EXPERIMENTAL","The research study procedures include: screening for eligibility and study treatment including daily PBMT and clinical evaluations. Participants will receive the study treatment daily from the start of conditioning chemotherapy to day +20, or discharge (if you are able to be discharged from the hospital prior to day +20), whichever occurs first\n\n-THOR LX2.3 with LED Lollipop",[13],"Device: THOR LX2.3 with LED Lollipop",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","THOR LX2.3 with LED Lollipop","The intraoral PBMT device will be placed inside of the mouth to deliver the therapeutic light. Each treatment is approximately 2-3 minutes in duration. PBMT will be administered daily starting from the start of conditioning through day +20, or discharge if prior to day +20, with 27 consecutive days defined as a maximum PBMT treatment duration",[9],null,[22,26],{"name":23,"affiliation":24,"role":25},"Kentaro Ikeda, DDS, MPH","Brigham and Women's Hospital","PRINCIPAL_INVESTIGATOR",{"name":27,"affiliation":24,"role":25},"Nathaniel S. Treister, DMD, DMSc",[29],{"name":30,"role":31,"phone":32,"phoneExt":20,"email":33},"Kentaro Ikeda, DDS,MPH","CONTACT","617-732-6570","kikeda4@bwh.harvard.edu",[35],{"facility":24,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Boston","Massachusetts","02115","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-71.05977,42.35843,{"lat":46,"lon":45},[49,51,52],{"name":50,"role":31,"phone":32,"phoneExt":20,"email":33},"Kentaro Ikeda, DDS, DMSc",{"name":23,"role":25,"phone":20,"phoneExt":20,"email":20},{"name":27,"role":25,"phone":20,"phoneExt":20,"email":20},{"type":25,"investigatorFullName":23,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Principal Investigator",[56],{"name":57,"class":58},"THOR Photomedicine Ltd","UNKNOWN","100465033","intraoral-photobiomodulation-therapy-to-prevent-oral-mucositis-in-patients-undergoing-hematopoietic-cell-transplantation-100465033",false,"NCT05335434","Intraoral Photobiomodulation Therapy to Prevent Oral Mucositis in Patients Undergoing Hematopoietic Cell Transplantation","A Single Center Pilot Study of Intraoral Photobiomodulation Therapy for the Prevention of Oral Mucositis in Patients Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation","Inclusion Criteria:\n\n* Planned to undergo myeloablative allogeneic HCT using FluBu4 conditioning and Tac-Mtx GVHD prophylaxis.\n* Age ≥18 years.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Participants who have had treatment with intraoral PBMT within four weeks of admission for HSCT.\n* Participants who have a history of radiation therapy to the head and neck.\n* Participants who have a history of photosensitivity or underlying disease with known photosensitivity.\n* Participants who are planned to receive palifermin for OM prevention.","ALL","18 Years",{"count":69,"type":70},20,"ESTIMATED","INTERVENTIONAL",[73],"NA","This is a single center pilot study evaluating intraoral photobiomodulation for the prevention of oral mucositis in patients undergoing myeloablative allogeneic hematopoietic cell transplantation (alloHCT). Patients who are planned for alloHCT will receive daily intraoral photobiomodulation therapy (PBMT) using a novel LED device.\n\nThe name of the study device involved in this study is:\n\n\\- THOR LX2.3 with LED Lollipop",[76,77,78,79],"Myeloablative Allogeneic Hematopoietic Cell Transplantation","Intraoral Photobiomodulation Therapy","Oral Mucositis","Mucosal Ulcer",[81,77,78,79],"Myeloablative Allogeneic Hematopoietic Cell Transplantation (HCT)","2025-12-08",{"date":84,"type":85},"2025-12-15","ACTUAL",{"date":87,"type":85},"2022-06-10",{"date":89,"type":70},"2026-07-19",{"name":5,"class":6},1]